ApconiX Welcomes Dr Bjorn Dahl ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Gothenburg. Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development [...]
Wishing Everyone Happy Holidays The ApconiX team enjoyed a festive lunch at the Coach and Four in Wilmslow this Christmas. We'd all like to take this opportunity to wish everyone Happy Holidays, a Merry Christmas and a very Happy and Prosperous New Year. Here's to making lots of better [...]
Choosing the right non-clinical CRO Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical [...]
ApconiX Celebrates EUROTOX EUROTOX 2018 was a great success with many excellent sessions, posters and keynote lectures. There were more than 1400 attendees from >50 countries giving an outstanding opportunity for networking and learning. Highlights included the Merit award lecture from Sam Cohen (University of Nebraska) who talked about [...]
Dr Paul Duffy will be speaking at EUROTOX this September. On Monday 3rd of September at 16:30 in the SILVER Hall Paul will address “Old drugs in new guises: the toxicology of repurposing” chaired and introduced by Ruth Roberts and Dr Miranda Cornet from UCB in Belgium. Paul will present case studies to illustrate the [...]
Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several years. Though there is [...]
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients. Dr Richard Knight of Alderley Park-based ApconiX told last month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to [...]
Accelerating Cancer Drug Development -From target to patients, BioNow will be hosting this event at Alderley Park on the 27th of February 2018. Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst [...]
XenoGesis is teaming up with Sygnature Discovery and DMDG to host the forthcoming meeting on predictive toxicology in Discovery DMPK. The one-day meeting will be held at BioCity, Nottingham on Thursday 22nd March 2018. The meeting will provide a forum for the exchange of ideas between members of the DMPK and toxicology research communities. The event will bring together talks from [...]
A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety [...]
